IL-6 serum levels are elevated in Parkinson's disease patients with fatigue compared to patients without fatigue

Journal of the Neurological Sciences

Volumn 370, Issue , 2016, Pages 153-156

  Pereira, Jéssica Ramos ^a   Santos, Lílian Viana dos ^a   Santos, Renata Maria Silva ^a   Campos, Ana Luíza Figueiredo ^a   Pimenta, André Lana ^a   de Oliveira, Mateus Silva ^a   Bacheti, Geander Gaburro ^a   Rocha, Natália Pessoa ^a   Teixeira, Antônio Lúcio ^a   Christo, Paulo Pereira ^b   Scalzo, Paula Luciana ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Centro de Especialidades Médicas da Santa Casa de Belo Horizonte   (Brazil)

Author keywords

Fatigue; Inflammation; Interleukin 6; Parkinson's disease

Indexed keywords

INTERLEUKIN 6; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; ANTIPARKINSON AGENT; BIOLOGICAL MARKER; IL6 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL OUTCOME; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; FATIGUE; FEMALE; FUNCTIONAL STATUS; HUMAN; MALE; MIDDLE AGED; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; UNIFIED PARKINSON DISEASE RATING SCALE; BLOOD; COMPARATIVE STUDY; COMPLICATION; MENTAL HEALTH; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; BIOMARKERS; FATIGUE; FEMALE; HUMANS; INTERLEUKIN-6; LOGISTIC MODELS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PARKINSON DISEASE; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84988584597     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2016.09.030     Document Type: Article

References (40)

1. [1] Friedman, J.H., Brown, R.G., Comella, C., et al. Fatigue in Parkinson's disease: a review. Mov. Disord. 22 (2007), 297–308.
2. [2] Havlikova, E., Rosenberger, J., Nagyova, I., et al. Impact of fatigue on quality of life in patients with Parkinson's disease. Eur. J. Neurol. 15 (2008), 475–480.
3. [3] Bruno, A.E., Sethares, K.A., Fatigue in Parkinson disease: an integrative review. J. Neurosurg. Nurs. 47 (2015), 146–153.
4. [4] Dogan, V.B., Koksal, A., Dirican, A., et al. Independent effect of fatigue on health-related quality of life in patients with idiopathic Parkinson's disease. Neurol. Sci. 36 (2015), 2221–2226.
5. [5] Abe, K., Takanashi, M., Yanagihara, T., et al. Pergolide mesilate may improve fatigue in patients with Parkinson's disease. Behav. Neurol. 13 (2001–2002), 117–121.
6. [6] Morris, G., Berk, M., Walder, K., et al. Central pathways causing fatigue in neuroinflammatory and autoimmune illnesses. BMC Med. 13 (2015), 1–23.
7. [7] Lindqvist, D., Kaufman, E., Brundin, L., et al. Non-motor symptoms in patients with Parkinson's disease – correlations with inflammatory cytokines in serum. PLoS One 7 (2012), 1–7.
8. [8] De Sanctis, V., Agolli, L., Visco, V., et al. Cytokines, fatigue, and cutaneous erythema in early stage breast cancer patients receiving adjuvant radiation therapy. Biomed. Res. Int., 1-7, 2014.
9. [9] Zimmer, P., Mierau, A., Bloch, W., et al. Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine. Leuk. Lymphoma 56 (2015), 347–352.
10. [10] Baidina, T.V., Torgan, T.I., Demchuk, N.D., et al. Inflammatory mechanisms of fatigue syndrome in Parkinson's disease. Zh Nevrol Psikhiatr Im S S Korsakova. 115 (2015), 61–64.
11. [11] Louati, K., Berenbaum, F., Fatigue in chronic inflammation - a link to pain pathways. Arthritis Res. Ther. 17 (2015), 1–10.
12. [12] Gerber, L., Estep, M., Stepanova, M., et al. Effects of viral eradication with ledipasvir and sofosbuvir, with or without ribavirin, on measures of fatigue in patients with chronic hepatitis C virus infection. Clin. Gastroenterol. Hepatol. 14 (2016), 156–164.
13. [13] Barnum, C.J., Tansey, M.G., Neuroinflammation and non-motor symptoms: the dark passenger of Parkinson's disease?. Curr. Neurol. Neurosci. Rep. 12 (2012), 350–358.
14. [14] Rocha, N.P., De Miranda, A.S., Teixeira, A.L., Insights into neuroinflammation in Parkinson's disease: from biomarkers to anti-inflammatory based therapies. Biomed. Res. Int., 1-12, 2015.
15. [15] Herrero, M.T., Estrada, C., Maatouk, L., et al. Inflammation in Parkinson's disease: role of glucocorticoids. Front. Neuroanat. 9 (2015), 1–12.
16. [16] Reale, M., Iarlori, C., Thomas, A., et al. Peripheral cytokines profile in Parkinson's disease. Brain Behav. Immun. 23 (2009), 55–63.
17. [17] Scalzo, P., Kummer, A., Cardoso, F., Teixeira, A.L., Increased serum levels of soluble tumor necrosis factor-α receptor-1 in patients with Parkinson's disease. J. Neuroimmunol. 216 (2009), 122–125.
18. [18] Scalzo, P., Kummer, A., Cardoso, F., Teixeira, A.L., Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci. Lett. 468 (2010), 56–58.
19. [19] Rocha, N.P., Teixeira, A.L., Scalzo, P.L., et al. Plasma levels of soluble tumor necrosis factor receptors are associated with cognitive performance in Parkinson's disease. Mov. Disord. 29 (2014), 527–531.
20. [20] Hughes, A.J., Ben-Shlomo, Y., Daniel, S.E., et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 42 (1992), 1142–1146.
21. [21] Brucki, S.M.D., Nitrini, R., Caramelli, P., Bertolucci, P.H.F., et al. Suggestions for utilization of the mini-mental state examination in Brazil. Arq. Neuropsiquiatr. 61 (2003), 777–781.
22. [22] Fahn, S., Elton, E., The UPDRS development committee. Unified Parkinson's Disease Rating Scale. Recent Developments in Parkinson's Disease, 153–163, 1987.
23. [23] Hoehn, M.M., Yahr, M.D., Parkinsonism: onset, progression and mortality. Neurology 17 (1967), 427–442.
24. [24] Gorenstein, C., Andrade, L., Validation of a Portuguese version of the Beck depression inventory and the state-trait anxiety inventory in Brazilian subjects. Braz. J. Med. Biol. Res. 29 (1996), 453–457.
25. [25] Kummer, A., Scalzo, P., Cardoso, F., Teixeira, A.L., Evaluation of fatigue in Parkinson's disease using the Brazilian version of Parkinson's fatigue scale. Acta Neurol. Scand. 123 (2011), 130–136.
26. [26] Rohleder, N., Aringer, M., Boentert, M., Role of interleukin-6 in stress, sleep, and fatigue. Ann. N. Y. Acad. Sci. 1261 (2012), 88–96.
27. [27] Bossola, M., Di Stasio, E., Giungi, S., et al. Fatigue is associated with serum interleukin-6 levels and symptoms of depression in patients on chronic hemodialysis. J. Pain Symptom Manag. 49 (2015), 578–585.
28. [28] Malekzadeh, A., Van de Geer-Peeters, W., De Groot, V., et al. Fatigue in patients with multiple sclerosis: is it related to pro- and anti-inflammatorycytokines?. Dis. Markers, 1-7, 2015.
29. [29] Peters, A., The energy request of inflammation. Endocrinology 147 (2006), 4550–4552.
30. [30] Sozen, T., Tsuchiyama, R., Hasegawa, Y., et al. Role of interleukin-1beta in early brain injury after subarachnoid hemorrhage in mice. Stroke 40 (2009), 2519–2525.
31. [31] Morris, G., Maes, M., A neuro-immune model of myalgic encephalomyelitis/chronic fatigue syndrome. Metab. Brain Dis. 28 (2013), 523–540.
32. [32] Ida, T., Hara, M., Nakamura, Y., et al. Cytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxide. Neurosci. Lett. 432 (2008), 232–236.
33. [33] Zhang, H., Wu, C.Y., Wang, W., et al. Interneuronal synapses formed by motor neurons appear to be glutamatergic. Neuroreport 22 (2011), 809–813.
34. [34] Hagell, P., Brundin, L., Towards an understanding of fatigue in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 80 (2009), 489–492.
35. [35] Alves, G., Wentzel-Larsen, T., Larsen, J.P., Is fatigue an independent and persistent symptom in patients with Parkinson's disease?. Neurology 63 (2004), 1908–1911.
36. [36] Nakamura, T., Hirayama, M., Hara, T., et al. Does cardiovascular autonomic dysfunction contribute to fatigue in Parkinson's disease?. Mov. Disord. 26 (2011), 1869–1874.
37. [37] Skorvanek, M., Nagyova, I., Rosenberger, J., et al. Clinical determinants of primary and secondary fatigue in patients with Parkinson's disease. J. Neurol. 260 (2013), 1554–1561.
38. [38] Fabbrini, G., Latorre, A., Suppa, A., et al. Fatigue in Parkinson's disease: motor or non-motor symptom?. Parkinsonism Relat. Disord. 19 (2013), 148–152.
39. [39] Solla, P., Cannas, A., Mulas, C.S., et al. Association between fatigue and other motor and non-motor symptoms in Parkinson's disease patients. J. Neurol. 261 (2014), 382–391.
40. [40] Stocchi, F., Abbruzzese, G., Ceravolo, R., et al. Prevalence of fatigue in Parkinson disease and its clinical correlates. Neurology 83 (2014), 215–220.